162360-77-2

Upstream product

• 1383437-37-3 N-[3-(4-benzyloxy-phenyl)-1,1-bis-hydroxymethyl-propyl]-acetamide 
• 4397-53-9 p-benzyloxybenzaldehyde 
• 163930-30-1 2-<4-(Benzyloxy)phenyl>ethyl iodide 
• 209476-18-6 diethyl 2-acetamido-2-(4-(benzyloxy)phenethyl)malonate 
• 162360-75-0 2-acetamido-2-(4-(benzyloxy)phenethyl)propane-1,3-diyl diacetate 
• 36438-64-9 p-benzyloxystyrene 
• 61439-59-6 2-(4-benzyloxyphenyl)ethanol 
• 123-08-0 4-hydroxy-benzaldehyde 
• 1070895-16-7 2-(acetylamino)-2-[(acetyloxy)methyl]-4-(4-{[1-(tert-butyl)-1,1-dimethylsilyl]oxy}phenyl)butyl acetate 

Downstream Products

• 1070895-18-9 2-(acetylamino)-2-[(acetyloxy)methyl]-4-{4-[(trifluoromethanesulfonyl)oxy]phenyl}butyl acetate 
• 162358-42-1 2-acetamido-2-(4-(heptyloxy)phenethyl)propane-1,3-diyl diacetate 
• 162360-27-2 2-acetamido-2-(4-(pentanetyloxy)phenethyl)propane-1,3-diyl diacetate 
• 162360-26-1 2-amino-2-(4-(pentanetyloxy)phenethyl)propane-1,3-diol hydrochloride 
• 162361-04-8 2-amino-2-(4-(octyloxy)phenethyl)propane-1,3-diol hydrochloride 

Relevant academic research and scientific papers

Exploring physicochemical space: Via a bioisostere of the trifluoromethyl and ethyl groups (BITE): Attenuating lipophilicity in fluorinated analogues of Gilenya for multiple sclerosis

The direct, catalytic vicinal difluorination of terminal alkenes via an I(i)/I(iii) manifold was exploited to install a chiral, hybrid bioisostere of the CF3 and Et groups (BITE) in Gilenya; the first orally available drug for the clinical management of Multiple Sclerosis (MS). This subtle fluorination pattern allows lipophilicity (logD) to be tempered compared to the corresponding CF3 and Et derivatives (CH2CH3 > CH2CF3 > CHFCH2F).

TX-2152: A conformationally rigid and electron-rich diyne analogue of FTY720 with in vivo antiangiogenic activity

We designed FTY720 analogues with conformationally rigid and electron-rich acetylenic chains as antiangiogenic agents (the monoyne 1: TX-2148, the diyne 2: TX-2152, the triyne 3: TX-2256). Molecular orbital (MO) calculations of our designed acetylenic ana

2-amino-1,3-propanediol compound and immunosuppressant

2-Amino-1,3-propanediol compounds of the formula (I) STR1 wherein R is an optionally substituted straight- or branched carbon chain, an optionally substituted aryl, an optionally substituted cycloalkyl or the like, and R2, R3, R4 and R5 are the same or different and each is a hydrogen, an alkyl, an aralkyl, an acyl or an alkoxycarbonyl, pharmaceutically acceptable salts thereof and immunosuppressants comprising these compounds as active ingredients. The 2-amino-1,3-propanediol compounds of the present invention show immunosuppressive action and are useful for suppressing rejection in organ or bone marrow tranplantation, prevention and treatment of autoimmune diseases or as reagents for use in medicinal and pharmaceutical fields.